Harms of TNF inhibitors in rheumatic diseases: a focused review of the literature

被引：1

作者：

Jain, Archana ^{[1
]}

Singh, Jasvinder A. ^{[1
,2
,3
,4
,5
]}

机构：

[1] Univ Alabama Birmingham, Sch Med, Dept Med, Birmingham, AL USA

[2] Univ Alabama Birmingham, Sch Publ Hlth, Div Epidemiol, Birmingham, AL 35294 USA

[3] Birmingham VA Med Ctr, Med Serv, Birmingham, AL USA

[4] Birmingham VA Med Ctr, Ctr Surg Med Acute Care Res & Transit, Birmingham, AL USA

[5] Mayo Clin, Coll Med, Dept Orthoped Surg, Rochester, MN USA

来源：

IMMUNOTHERAPY | 2013年 / 5卷 / 03期

关键词：

adverse effect; biologic; harm; rheumatic disease; rheumatoid arthritis; TNF biologic; TNF inhibitor; TUMOR-NECROSIS-FACTOR; SERIOUS BACTERIAL-INFECTIONS; MODIFYING ANTIRHEUMATIC DRUGS; FACTOR THERAPY; BRITISH-SOCIETY; HEART-FAILURE; FACTOR ANTAGONISTS; OPPORTUNISTIC INFECTIONS; BIOLOGICS REGISTER; ELDERLY-PATIENTS;

D O I：

10.2217/IMT.13.10

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

A focused review of the risk of harms of anti-TNF inhibitors in adult rheumatic diseases was performed. An increased risk of serious infections, tuberculosis and other opportunistic infections has been reported across various studies, with etanercept appearing to have a modestly better safety profile in terms of tuberculosis and opportunistic infections, and infliximab posing a higher risk of serious infections. Evidence suggests no increase in risk of cancer with anti-TNF biologics, but there is an increased risk of non-melanoma skin cancer. Elderly patients appear to be at increased risk of incident or worsening heart failure with anti-TNF biologic use.

引用

页码：265 / 299

页数：35

共 50 条

[1] INCIDENCE OF TUBERCULOSIS IN PATIENTS WITH RHEUMATIC DISEASES USING TNF INHIBITORS: A SYSTEMATIC REVIEW
Sartori, Natalia
Andrade, Nicole
Chakr, Rafael
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 2077 - 2078
[2] Musculoskeletal and Rheumatic Diseases Induced by Immune Checkpoint Inhibitors: A Review of the Literature
Benfaremo, Devis
Manfredi, Lucia
Luchetti, Michele Maria
Gabrielli, Armando
[J]. CURRENT DRUG SAFETY, 2018, 13 (03) : 150 - 164
[3] Risks associated with use of TNF inhibitors in children with rheumatic diseases
Marino, Achille
Giani, Teresa
Cimaz, Rolando
[J]. EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2019, 15 (02) : 189 - 198
[4] Bariatric Surgery and Rheumatic Diseases: A Literature Review
Gallo, Gaetano
Candilio, Giuseppe
De Luca, Emilia
Iannicelli, Angelo
Sciaudone, Guido
Pellino, Gianluca
Sacco, Rosario
Selvaggi, Francesco
Sammarco, Giuseppe
[J]. REVIEWS ON RECENT CLINICAL TRIALS, 2018, 13 (03) : 176 - 183
[5] USE OF DIMETHYLSULFOXIDE IN RHEUMATIC DISEASES (REVIEW OF THE LITERATURE)
LAPSHIN, DE
RUDENKO, VG
RUDENKO, YV
[J]. VRACHEBNOE DELO, 1991, (01): : 14 - 19
[6] COMPARISON OF TNF-α INHIBITORS EFFICACY BETWEEN RHEUMATIC DISEASES AND INFLAMMATORY BOWEL DISEASES
Nuriakhmetova, T.
Abdulganieva, D.
Valeeva, I. K.
Shevnina, J.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1516 - 1516
[7] TNF alpha inhibitors in children with rheumatic diseases in Switzerland; establishment of a database
Bolt, I.
Saurenmann, T.
Berthet, G.
Bolz, D.
Hofer, M.
Kaiser, D.
Sauvain, M. J.
[J]. SWISS MEDICAL WEEKLY, 2007, 137 : 5S - 5S
[8] TROUGH LEVELS OF TNF-A INHIBITORS AND THEIR IMMUNOGENICITY IN THE TREATMENT OF RHEUMATIC DISEASES AND INFLAMMATORY BOWEL DISEASES
Nuriakhmetova, T.
Valeeva, I. K.
Shevnina, J.
Abdulganieva, D.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 1269 - 1270
[9] Damage indices in rheumatic diseases: A systematic review of the literature
Ferdowsi, N.
Stevens, W.
Baron, M.
Nikpour, M.
[J]. SEMINARS IN ARTHRITIS AND RHEUMATISM, 2019, 49 (01) : 27 - 34
[10] Peer Support in Rheumatic Diseases: A Narrative Literature Review
Karp, Nathan
Yazdany, Jinoos
Schmajuk, Gabriela
[J]. PATIENT PREFERENCE AND ADHERENCE, 2023, 17 : 2433 - 2449

← 1 2 3 4 5 →